Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade

Group 1 - Invivyd Inc. has selected VBY329 as a monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) in neonates, infants, and children [1] - VBY329 has demonstrated 1.5-fold greater antiviral potency than clesrovimab in in vitro testing, and the company aims for IND readiness in the second half of 2026 [2][4] - The RSV prophylaxis market for babies and children under 24 months is identified as a rapidly growing pharmaceutical market, providing significant opportunities for the company [3] Group 2 - D. Boral Capital downgraded Invivyd to a Hold from a Buy, reflecting concerns about the pipeline and balance sheet expectations [4] - Invivyd utilizes a proprietary technology platform to create medicines that are more potent and resistant to virus evolution than the human immune system [5]